Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etripamil - Milestone Pharmaceuticals

Next Previous
Drug Profile

Etripamil - Milestone Pharmaceuticals

Alternative Names: (-)-MSP-2017; CARDAMYST; MSP-2017; MSP-2017A; MSP-2017B; TACHYMIST

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Milestone Pharmaceuticals
  • Class Alkanes; Amines; Antiarrhythmics; Benzoates; Esters; Ischaemic heart disorder therapies; Nitriles; Small molecules
  • Mechanism of Action L-type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Paroxysmal supraventricular tachycardia
  • Phase III Atrial fibrillation
  • Discontinued Angina pectoris

Most Recent Events

  • 23 Mar 2026 Everest Medicines acquires Etripamil from Corxel Pharmaceuticals in China, Hong Kong, Macau, Taiwan
  • 23 Mar 2026 Milestone Pharmaceuticals anticipates National Medical Products Administration (NMPA) approval of New Drug Application (NDA) for Paroxysmal supraventricular tachycardia in the third quarter of 2026
  • 20 Mar 2026 The EMA is expected to issue a regulatory decision on the Marketing Authorization Application (MAA) by the first half of 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top